• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Coherus Oncology, Inc. - Common Stock (NQ:CHRS)

    1.305 +0.105 (+8.75%)
    Streaming Delayed Price Updated: 2:31 PM EST, Dec 8, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,488,458
    Open 1.230
    Bid (Size) 1.300 (2,300)
    Ask (Size) 1.310 (7,100)
    Prev. Close 1.200
    Today's Range 1.230 - 1.350
    52wk Range 0.7100 - 1.890
    Shares Outstanding 116,236,018
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
    -6 Years Long-term survival data reinforce potential benefit to patient survival in treating recurrent or metastatic nasopharyngeal carcinoma with LOQTORZI in combination with chemotherapy - 
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
    From Coherus Oncology, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -6.8%
    -6.8%
    1 Month
    -2.6%
    -2.6%
    3 Month
    -4.7%
    -4.7%
    6 Month
    +52.7%
    +52.7%
    1 Year
    -23.2%
    -23.2%

    More News

    Read More
    News headline image
    Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Coherus BioSciences's Earnings Outlook ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
    Via Benzinga
    News headline image
    Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology to Participate in Upcoming Investor Conferences
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Insights Ahead: Coherus BioSciences's Quarterly Earnings ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For May 12, 2025 ↗
    Via Benzinga
    News headline image
    4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
    Via Benzinga
    News headline image
    Coherus Oncology Announces Poster Presentation at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
    Via Benzinga
    News headline image
    Coherus Oncology to Participate in Upcoming Investor Conferences
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus (CHRS) Q2 Revenue Jumps 10% ↗
    Via The Motley Fool
    News headline image
    Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
    From Coherus Oncology, Inc.
    Via GlobeNewswire
    News headline image
    Which stocks are moving after the closing bell on Friday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)
    From Coherus BioSciences, Inc.
    Via GlobeNewswire
    News headline image
    Top movers in Friday's after hours session ↗
    Via Chartmill
    News headline image
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
    From Coherus BioSciences, Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Coherus Oncology, Inc. - Common Stock publicly traded?
    Yes, Coherus Oncology, Inc. - Common Stock is publicly traded.
    What exchange does Coherus Oncology, Inc. - Common Stock trade on?
    Coherus Oncology, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Coherus Oncology, Inc. - Common Stock?
    The ticker symbol for Coherus Oncology, Inc. - Common Stock is CHRS on the Nasdaq Stock Market
    What is the current price of Coherus Oncology, Inc. - Common Stock?
    The current price of Coherus Oncology, Inc. - Common Stock is 1.305
    When was Coherus Oncology, Inc. - Common Stock last traded?
    The last trade of Coherus Oncology, Inc. - Common Stock was at 12/08/25 02:31 PM ET
    What is the market capitalization of Coherus Oncology, Inc. - Common Stock?
    The market capitalization of Coherus Oncology, Inc. - Common Stock is 151.69M
    How many shares of Coherus Oncology, Inc. - Common Stock are outstanding?
    Coherus Oncology, Inc. - Common Stock has 152M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.